Discovery of a Highly Potent, Orally Active Mitosis/Angiogenesis Inhibitor R1530 for the Treatment of Solid Tumors
ACS Medicinal Chemistry Letters2013Vol. 4(2), pp. 259–263
Citations Over Time
Jinjun Liu, Brian Higgins, G Ju, Kenneth Kolinsky, Kin‐Chun Luk, Kathryn Packman, Giacomo Pizzolato, Yi Ren, Kshitij Thakkar, Christian Tovar, Zhuming Zhang, Peter M. Wovkulich
Abstract
A new series of 7,8-disubstituted pyrazolobenzodiazepines based on the lead compound 1 have been synthesized and evaluated for their effects on mitosis and angiogenesis. Described herein is the design, synthesis, SAR, and antitumor activity of these compounds leading to the identification of R1530, which was selected for clinical evaluation.
Related Papers
- → Overexpression of the p53-inducible brain-specific angiogenesis inhibitor 1 suppresses efficiently tumour angiogenesis(2002)48 cited
- Progress on the antitumor effect of angiogenesis inhibitor TNP-470(2007)
- A new potent angiogenesis inhibitor,FR-118487(1991)
- → Regulation of angiogenesis in human hepatomas: possible involvement of p53-inducible inhibitor of vascular endothelial cell proliferation(1999)13 cited
- → An endothelium-derived angiogenesis inhibitor vasohibin and its significance in tumor angiogenesis(2006)